Expert Review of Anticancer Therapy

Article	Citations
Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence	83
Nanotechnology meets liver cancer: liposomal immunotherapy strategies for hepatocellular carcinoma	54
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma	52
Clinical characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphoma	39
Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia	37
Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?	36
The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs	34
Oral decitabine and cedazuridine for the treatment of myelodysplastic syndromes: an integrated review of clinical, economic and patient-centered evidence	32
PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects	27
Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review	27
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review	26
Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis	24
Current status and novel insights into the role of metastasectomy in the era of immunotherapy	24
Progress in histology specific treatments in soft tissue sarcoma	22
The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan	22
Palbociclib in endocrine-resistant metastatic breast cancer: real-world outcomes	21
Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer	20
Importance of radiation-related cognitive decline in older adults who receive cranial radiation	19
Progress in the development of tissue-based biomarkers for urothelial cancer	17
Prognostic and clinicopathological value of myeloid-derived suppressor cells in lung cancer: a comprehensive systematic review and meta-analysis	17
Primary effusion lymphoma: therapeutic strategies targeting viral and cellular mechanisms	16
Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancer	16
Current management of familial adenomatous polyposis	16
Prognostic factors of undifferentiated embryonal sarcoma of the liver in children: a SEER-based study	16
An evaluation of selinexor as a maintenance therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma	15

CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer	14
Supportive care in pediatric acute myeloid leukemia:Expert-based recommendations of the NOPHO-DB-SHIP consortium	14
Determining factors of neuroplasticity in patients with brain tumors: impact of connectome and artificial intelligence. A narrative review	14
The importance of autophagy in multiple myeloma	13
Early detection of hepatocellular carcinoma: roadmap for improvement	13
Prostate cancer prediction through a hybrid deep learning method applied to histopathological image	13
Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population	13
NRF2/KEAP1 signaling inhibitors in gynecologic cancers	13
Elacestrant in metastatic breast cancer: current advancements and future perspectives	13
Current status of robotic surgery for hepato-pancreato-biliary malignancies	12
A systematic review to summarize treatment patterns, guidelines, and characteristics of patients with renal cell carcinoma in the Asia-Pacific region	12
What are the key considerations for deciding on the use of CAR T-cell therapy for patients with follicular lymphoma?	12
EGFR-TKI plus chemotherapy versus TKI monotherapy in advanced EGFR-mutant NSCLC with high PD-L1 expression: a real-world retrospective study	12
Deciding individual treatment for primary retroperitoneal sarcoma	12
Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives	12
Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: multicentre experience in a low-middle-income country	12
Outcomes after the watch-and-wait strategy and local excision treatment for rectal cancer: a meta-analysis	12
Management of breast cancer diagnosed during pregnancy: global perspectives	11
The trend toward more target therapy in pancreatic ductal adenocarcinoma	11
Targeting GPRC5D in multiple myeloma	11
CRISPR: a precise genome editing strategy for the treatment of hepatocellular carcinoma	11
From macroscopic clearance to molecular eradication: paradigm shift and future perspectives in the detecting of residual lesions after transurethral resection of bladder tumors	11
Unveiling the power of PARP inhibitors: a meta-analysis on newly diagnosed advanced ovarian cancer maintenance therapy	11
Evaluating the efficacy and safety of trebananib in treating ovarian cancer and non-ovarian cancer patients: a meta-analysis and systematic review	11
The long and winding road of faecal microbiota transplants to targeted intervention for improvement of immune checkpoint inhibition therapy	11
Diagnostic significance of miRNAs as potential biomarkers for human renal cell carcinoma: a systematic review and meta-analysis	11
Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and	11
Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond	10
NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?	10
The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer	10
Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity	10
JARID2 activation by NFYA promotes stemness of triple-negative breast cancer cells through the PI3K/AKT pathway	10
Novel breakthroughs in advanced prostate cancer management	10
Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC)	10
Nivolumab plus ipilimumab in malignant pleural mesothelioma	10
Pretreatment hyperferritinaemia as an independent prognostic marker in metastatic solid tumors treated with immune checkpoint inhibitors	10
What’s to come in PSMA therapies and diagnostics: A summary of clinical trials involving PSMA radioligand-based therapeutic and/or diagnostic approaches with active recruitment	10
Differentiated thyroid cancer and positron emission computed tomography: when, how and why?	10
PROTACs in action: a novel strategy for pancreatic cancer	10
Efficacy and safety of anti-angiogenesis agents combined with chemoradiotherapy in the treatment of locally advanced cervical cancer: a meta-analysis of randomized controlled trials	10
Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer	10
Anticancer properties of histone deacetylase inhibitors – what is their potential?	10
Benign and malignant cardiac masses: long-term outcomes after surgical resection	9
Upper and lower limb cryotherapy as a preventive strategy for taxane-induced peripheral neuropathy in breast cancer patients: a systematic review and meta-analysis	9
Genetic investigation in patients with histological variants of bladder cancer: clinical implications	9
Image-guided radiotherapy (IGRT) in Lombardy, Italy: a survey by the Lombardy section of the Italian Association of Radiotherapy and Clinical Oncology (AIRO-Lombardy)	9
Emerging treatment options for prostate cancer	9
Drugging the DNA damage response in the clinic: going beyond PARP	9
Interventions to reduce the risk of side-effects of cancer treatments in childhood	9
Understanding the causes of recurrent HCC after liver resection and radiofrequency ablation	9

A neurocentric model of survivorship: rethinking success when the mind and nerves don’t recover	9
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials	9
Drug–drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors	9
Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer	9
Effect of flexible sigmoidoscopy-based screening on colorectal cancer incidence and mortality: an updated systematic review and meta-analysis of randomized controlled trials	8
Oligometastases in head and neck squamous cell carcinoma patients	8
Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers	8
The selection of targeted therapies for relapsed or refractory advanced renal cell carcinoma	8
Shedding light on the side effects of immunotherapies used for leukemia: an updated review of the literature	8
The Gustave Roussy immune score as a novel biomarker for predicting survival in patients with isocitrate dehydrogenase wild-type glioblastoma treated with the Stupp protocol	8
Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma	8
Compression therapy for the prevention of taxane-induced peripheral neuropathy in breast cancer: a systematic review and meta-analysis	8
Girentuximab imaging in renal cancer: diamond in the rough or just ZIRCON?	8
Venetoclax and beyond: New Horizons in CLL and AML therapy	8
LAG-3 is a promising inhibitory immune checkpoint for antitumor immunotherapy	8
Cemiplimab for locally advanced and metastatic basal cell carcinoma	8
Clinicopathological and prognostic significance of TIMP1 expression in gastric cancer: a systematic review and meta-analysis	8
Radiation-induced nasopharyngeal necrosis combined with local recurrence in nasopharyngeal carcinoma: diagnosis and treatment strategies	8
CRISPR–mRNA synergy: toward adaptive cancer immunotherapy	8
Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials	8
Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment	8
Ablative margins in percutaneous thermal ablation of hepatic tumors: a systematic review	7
The current treatment approach to adolescents and young adults with acute lymphoblastic leukemia (AYA-ALL): challenges and considerations	7
Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy	7
Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review	7
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?	7
The association between HALP score and survival in patients treated with immune checkpoint inhibitors	7
Medullary thyroid carcinoma: a narrative historical review	7
Contemporary management of advanced gastric and gastroesophageal adenocarcinomas	7
Is 2045 the best we can do? Mitigating the HPV-related oropharyngeal cancer epidemic	7
Immune checkpoint inhibition in early-stage triple-negative breast cancer	7
Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?	7
Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?	7
The relationship between statin use and breast cancer risk: NHANES 2003–2016 and Mendelian randomization study	7
Future directions for antibody-drug conjugates in urothelial cancer	7
From supportive care to adjunctive treatment: the evolution in time of physical exercise and nutrition in lung cancer	7
Epigenetic targeting in oral squamous cell carcinoma: mechanisms, therapies, and translational potential	7
Fixed-duration BTKi-venetoclax combinations in CLL: optimizing patient-centered care	7
Utilizing risk factors to guide treatment decisions in chronic lymphocytic leukemia	7
Circadian rhythm-based cancer therapy in randomised clinical trials	6
Inhibition of neuroactive ligand–receptor interaction pathway can enhance immunotherapy response in colon cancer: an in silico study	6
Overcoming common emerging barriers to effective neoadjuvant immunotherapies	6
Primary site and treatment impact in unresectable metastatic colorectal cancer	6
Addressing the need for more therapeutic options in neuroendocrine prostate cancer	6
Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer	6
Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancer	6
Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: where do we stand and where are we going?	6
Pathology, molecular biology, medical oncology, and radiotherapy implications of lung neuroendocrine neoplasm classification: a multidisciplinary perspective	6
Mucosa-associated lymphoid tissue lymphoma in thymus: a SEER analysis	6
Integrating PET/CT into breast cancer care: a review of recent developments	6
Management of oligometastatic and oligoprogressive renal cell carcinoma: an updated review	6
The assessment of circulating tumor DNA associated with Wnt/β-catenin signaling pathway as a diagnostic tool for liver cancer: a systematic review and meta-analysis	6
Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review	6
Predicting neoadjuvant chemoradiotherapy response with functional imaging and liquid biomarkers in locally advanced rectal cancer	6
Reevaluating the promise: is primary tumor surgery really the key to survival or just a misinterpretation in de novo stage IV breast cancer?	6
Clarifications and comments on “infrared radiation for cancer hyperthermia: the light to brighten up oncology”	5
Diagnostic performance of urine and blood microRNAs for bladder cancer: a meta-analysis	5
FLT3 -mutated AML: immune evasion through exosome-mediated mechanisms and innovative combination therapies targeting immune escape	5
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma	5
Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis	5
Prognostic value of circulating long non-coding RNAs in colorectal cancer patients: a meta-analysis	5
Is the ketogenic diet still controversial in cancer treatment?	5
Bevacizumab-containing treatment for relapsed or refractory Wilms tumor	5
Efficacy and safety of neoadjuvant therapy for triple-negative breast cancer: a Bayesian network meta-analysis	5
Prognostic value of the body composition parameters in patients with colorectal liver metastases undergoing intra-arterial treatment	5
Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer – a review of current evidence for and against the use of anti-HER2 treatment regimens	5
Development of a nomogram for predicting postoperative recurrence of cervical intraepithelial neoplasia using immunohistochemical and clinical parameters	5
Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitors	5
Efficacy of doxorubicin and lipiodol therapy by trans-arterial chemoembolization in hepatocellular carcinoma Egyptian patients and relation to genetic polymorphisms	5
The optimal management of brain metastases from gestational trophoblastic neoplasia	5
Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis	5
Toward clinical translation of AI-Led drug discovery in endometrial cancer	5
Neutrophil-to-lymphocyte ratio predicts survival of patients with rectal cancer receiving neo-adjuvant chemoradiation followed by radical resection: a meta-analysis	5
The role of planetary health in urologic oncology	5
The investigational role of cytoreductive stereotactic ablative radiation therapy (SABR) to the primary tumor in metastatic kidney cancer	5
How can we refine the prognostic stratification of triple-negative breast cancer?	5
Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for gastric cancer treatment: a systematic review and meta-analysis	5
First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC	5
Relugolix in the management of prostate cancer	5
The multidisciplinary management of locally advanced rectal cancer	5

Analysis of the efficacy of paclitaxel combined with bevacizumab intraperitoneal instillation in common gastrointestinal malignant peritoneal effusions and screening of prognostic indicators

5